Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
Blood Research
;
: 115-119, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-217663
ABSTRACT
BACKGROUND:
Abbreviated chemotherapy followed by radiotherapy or full cycles of chemotherapy is recommended as a standard treatment for limited-stage (LS) diffuse large B-cell lymphoma (DLBCL). After complete resection of tumors, however, Burkitt and childhood B-cell Non-Hodgkin lymphoma show favorable outcomes, even after abbreviated chemotherapy of only 2 or 3 cycles. We investigated the effectiveness of abbreviated chemotherapy in patients with LS DLBCL after complete tumor resection.METHODS:
We retrospectively reviewed 18 patients with LS DLBCL who underwent complete tumor resection followed by either 3 or 4 cycles of chemotherapy between March 2002 and May 2010.RESULTS:
With a median follow-up period of 57.9 months (range, 31.8-130.2 months), no patients experienced disease relapse or progression; however, 1 patient experienced secondary acute myeloid leukemia during follow-up. The 5-year progression-free survival rate and overall survival rate were 93.3% and 94.1%, respectively.CONCLUSION:
These results warrant further investigation into abbreviated chemotherapy as an alternative treatment for patients who have undergone complete resection of LS DLBCL.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Radioterapia
/
Recurrencia
/
Linfoma no Hodgkin
/
Linfocitos B
/
Leucemia Mieloide Aguda
/
Tasa de Supervivencia
/
Estudios Retrospectivos
/
Estudios de Seguimiento
/
Linfoma de Células B
/
Supervivencia sin Enfermedad
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Blood Research
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS